An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy

Market Analysis and Insights: Global Dexrazoxane Market
In 2020, the global Dexrazoxane market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Dexrazoxane Scope and Market Size
The global Dexrazoxane market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Dexrazoxane market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
250mg
500mg

Segment by Application
Hospital
Drug Store

By Company
Bedford Laboratories
Topotarget
Pharmacia and Upjohn
Gland Pharma
Mylan
West-Ward Pharms
Clinigen
Boehringer Ingelheim
Clinigen Healthcare
Aosaikang Pharmaceutical

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE